Remove <
article thumbnail

Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development

Fierce Pharma

In the role, he'll oversee the drugmaker's portfolio management and business development activities. .” | Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer.

article thumbnail

Drug Excipient Business Development Reports now Available on Amazon

Drug Patent Watch

Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Teva CEO Francis poaches business development head Angus Grant from BeiGene

Fierce Pharma

Teva’s CEO Richard Francis is adding to his constellation of new executives with a fresh business development hire from BeiGene. as its EVP of business development, the Israeli-American generics giant announced Friday. Teva has enlisted BeiGene's Angus Grant, Ph.D,

article thumbnail

Key Business Development Skills Every Manager Should Have

BioSpace

People working on business development are the ones responsible for dealing with the business side of the organization. Dealing with a lot of people, clients and a huge team is part of this job.

article thumbnail

Divya Iyer, VP Strategy & Business Development at GoodRx, showcases digital health innovations at Digital Pharma East conference

Fierce Pharma

Divya Iyer, VP Strategy & Business Development at GoodRx, showcases digital health innovations at Digital Pharma East conference. Thu, 11/10/2022 - 13:14.

article thumbnail

Mainz Biomed Appoints Steve Quinn as VP Business Development

BioTech 365

Mainz Biomed Appoints Steve Quinn as VP Business Development Mainz Biomed Appoints Steve Quinn as VP Business Development Highly experienced diagnostics business development executive appointed to lead growth initiatives across international markets and drive international sales of ColoAlert at-home screening … Continue reading →

article thumbnail

PharmaSGP: Expected business development in Q1 2021

BioTech 365

PharmaSGP: Expected business development in Q1 2021 Group revenues of € 12.4 DGAP-News: PharmaSGP Holding SE / Key word(s): Quarterly / Interim Statement 18.05.2021 / 07:30 The issuer is solely responsible for the content of this announcement. million and adjusted … Continue reading →